Inflammation is a devastating outcome of cerebrovascular diseases (CVD), namely stroke and atherosclerosis.
Numerous studies over the decade have shown that inflammasomes play a role in mediating inflammatory
reactions post cellular injury occurring after a stroke or a rupture of an atherosclerotic plaque. In view of this,
targeting these inflammatory pathways using different pharmacological therapies may improve outcomes in patients
with CVD. Here, we review the mechanisms by which inflammasomes drive the pathogenesis of stroke and
atherosclerosis. Also, discussed here are the possible treatment strategies available for inhibiting inflammasomes
or their up-stream/down-stream mediators.